Table 2

Visual acuity outcomes and re-treatment at each month

BCVA change from baseline in letters
PatientBaseline BCVAMo 1Mo 2Mo 3Mo 4Mo 5Mo 6Mo 7Mo 8Mo 9Mo 10Mo 11Mo 12
14093023353530301924302724
24891521 (R-P)211921232224252530
364−4−1146414668914
435−4−3−3−3−3−4−3257916
557122112252526252828242018
640−5230323836354035403840
7580712 (R-P)162218 (R-P)181412 (R-P)121015
8424−7−7−9−10−9−7−2−9−9−7−7
958−114715175 (R-F)14171917170 (R-F)
106353113−5 (R-F)−34−2−2−2−3 (R-F)
1158−410520−8 (R-F)−51−4 (R-F)5−11 (R-L)−22 (R-F)
1245162727273325353029241923
Mean (SE)50.7 (2.9)3.1 (2.1)9.8 (3.4)10.8 (3.5)13.8 (4.2)15.4 (4.6)11.6 (4.7)14.7 (4.5)15.1 (3.8)13.9 (4.2)15.1 (4.1)12.8 (4.2)12.3 (5.0)
p Value*0.1800.0230.0170.0150.0140.0710.0230.0040.0150.0100.0190.041
  • BCVA, best-corrected visual acuity; Mo, month; R-F, re-treatment due to leakage on fluorescein angiography without polyp identified; R-L, re-treatment by the discretion of a treating ophthalmologist using ranibizumab only; SER-P, re-treatment due to identified polyp.

  • * Mean BCVA at each month was compared for significant change from baseline using the Wilcoxon signed rank test.